Telesis Bio to Present at SynBioBeta 2023
May 23 2023 - 9:00AM
Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic
and synthetic biology solutions, today announced they will be
showcasing their benchtop automation solutions for synthetic
biology at SynBioBeta 2023 which is being held May 23-25 in
Oakland, California.
Telesis Bio will present in two speaker sessions: Todd R.
Nelson, Ph.D., CEO and Founder of Telesis Bio and David Brown,
Ph.D., Director R&D, RNAimmune will present “Beyond COVID:
Leveraging synthetic biology to advance the potential of mRNA-based
vaccines” on Tuesday May 23rd. RNAimmune will showcase the
application of the BioXp platform for accelerating their vaccine
discovery workflows. Daniel Gibson, Ph.D., CTO and Co-founder will
present “Streamlining molecular biology workflows throughout
biologics discovery” on Wednesday, May 24th. His presentation will
focus on the BioXp platform technology and updates on expanding
capabilities in synthetic biology, library preparation for NGS and
application of on-demand automated synthesis with SOLA EDS
technology.
The award winning BioXp® system and associated BioXp® De novo
and Select synthesis kits as well as NGS library prep kits provide
a complete automated solution for accelerating many synthetic
biology and genomics workflows throughout discovery. The system
assists researchers in optimizing their discovery process by
enabling sequence to screening in days, rather than weeks or months
with alternative methods.
Telesis Bio will also present in two poster sessions at the
conference: Qi Zhang, Ph.D. Scientist, R&D will present
“Automated solutions for addressing mRNA synthesis bottlenecks in
therapeutics discovery” and David Weiss, Director of Product
Management will present “Construction & Sequence Verification
of Custom Genomes: Using the BioXp to streamline design to test
workflow” to showcase application of the NGS library preparation
kits for plasmid sequencing on the BioXp platform.
For more information on Telesis Bio at SynBiobeta visit:
https://telesisbio.com/synbiobeta-2023/
About Telesis BioTelesis Bio is empowering
scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Telesis Bio is enabling rapid, accurate and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp® system consolidates, automates,
and optimizes the entire synthesis, cloning and amplification
workflow. As a result, it delivers virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Telesis Bio is a public company
based in San Diego. For more information, visit
www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp
are trademarks of Telesis Bio Inc.
Forward-Looking Statements This press release
contains forward-looking statements. All statements other than
statements of historical facts contained herein are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
include statements and guidance regarding Telesis Bio’s future
financial performance as well as statements regarding the future
release and success of new and existing products and services. Such
statements are based on current assumptions that involve risks and
uncertainties that could cause actual outcomes and results to
differ materially. These risks and uncertainties, many of which are
beyond our control, include risks described in the section entitled
Risk Factors and elsewhere in our Quarterly Report on Form 10-Q,
which was filed with the Securities and Exchange Commission on May
12, 2023, as amended on May 1, 2023. These forward-looking
statements speak only as of the date hereof and should not be
unduly relied upon. Telesis Bio disclaims any obligation to update
these forward-looking statements.
Contact:Jen CarrollVice President of Investor
Relationsjen.carroll@telesisbio.com
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From May 2023 to May 2024